GO:0106074 aminoacyl-tRNA metabolism involved in translational fidelity: Proofreading Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0106074 describes the proofreading and correction processes that ensure tRNAs carry the correct amino acid, a critical layer of translational fidelity [2, 7].
• Aminoacyl-tRNA synthetases (ARSs) often possess editing domains that hydrolyze mischarged tRNAs, preventing errors from entering the proteome [4, 7].
• Recent work shows that human protein synthesis requires aminoacyl-tRNA pivoting during proofreading, revealing dynamic quality-control mechanisms.
• Defects in this pathway are linked to cancer, neurodegeneration, and other diseases, making it a target for therapeutic intervention.
• The evolutionary history of ARSs is complex, with horizontal gene transfer and lineage-specific adaptations shaping fidelity mechanisms.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of GO:0106074 components in human cells.
Description
The fidelity of protein synthesis depends on the accurate pairing of amino acids with their cognate tRNAs, a process mediated by aminoacyl-tRNA synthetases (ARSs) [4, 7]. Errors at this step can lead to proteome-wide misfolding and cellular dysfunction. GO:0106074, aminoacyl-tRNA metabolism involved in translational fidelity, encompasses the proofreading and editing activities that detect and remove incorrectly charged amino acids from tRNAs, ensuring that only correctly aminoacylated tRNAs participate in translation [2, 7]. This term is essential for understanding how cells maintain translational accuracy and how failures contribute to disease. Research into this process has revealed diverse mechanisms, from hydrolytic editing by ARSs to post-transfer editing and ribosome-associated quality control [3, 7]. The evolutionary conservation and variation of these mechanisms underscore their fundamental importance. In this article, we explore the definition, mechanisms, key genes, and research methods for studying GO:0106074, with a focus on how CRISPR-based models can illuminate its roles in health and disease.
aminoacyl-tRNA metabolism involved in translational fidelity At A Glance
| GO ID | GO:0106074 |
|---|---|
| GO term | aminoacyl-tRNA metabolism involved in translational fidelity |
| Ontology | biological_process |
| Synonym | aminoacyl-tRNA correction, aminoacyl-tRNA editing, aminoacyl-tRNA proofreading |
| Major function | Proofreading and editing of aminoacyl-tRNAs to prevent misincorporation of amino acids during translation |
| Related processes | tRNA aminoacylation, translation, protein quality control |
| Key enzymes | Aminoacyl-tRNA synthetases (ARSs) with editing domains |
| Disease relevance | Cancer, neurodegeneration, mitochondrial disorders |
What Is GO:0106074?
GO:0106074 is defined as any process that detects whether an amino-acid-acetylated tRNA is charged with the correct amino acid, or removes incorrect amino acids from a charged tRNA. This process can be performed by tRNA synthases or by subsequent reactions after tRNA aminoacylation. In essence, it covers the proofreading and editing steps that safeguard the accuracy of tRNA charging, a prerequisite for translational fidelity [2, 7].
Why Is aminoacyl-tRNA metabolism involved in translational fidelity Important in Cell Biology?
Translational fidelity is fundamental to cellular health, and GO:0106074 represents a critical quality-control layer that prevents errors from being permanently encoded in proteins [2, 7]. Without efficient proofreading, mischarged tRNAs can lead to proteotoxic stress, which is implicated in aging and numerous diseases. Understanding this process provides insights into basic biology and offers potential therapeutic targets for diseases characterized by protein misfolding.
• Prevents amino acid misincorporation, which can cause protein misfolding and aggregation.
• Maintains proteome integrity and cellular homeostasis.
• Dysregulation is linked to cancer through altered translation and metabolic reprogramming.
• Mutations in ARSs cause Charcot-Marie-Tooth disease and other neuropathies.
• Mitochondrial ARS defects lead to severe mitochondrial diseases.
• Editing defects can trigger the integrated stress response and apoptosis.
• Provides targets for antibiotic development in bacteria.
• Influences immune surveillance by altering the antigen repertoire.
• Plays a role in aging and age-related diseases.
• Offers opportunities for CRISPR-based functional genomics.
What Happens During aminoacyl-tRNA metabolism involved in translational fidelity?
Aminoacylation and Initial Charging
In simple terms: First, each tRNA is paired with its correct amino acid by a synthetase enzyme.
The process begins with aminoacyl-tRNA synthetases (ARSs) catalyzing the attachment of amino acids to their cognate tRNAs, a step that is generally accurate but can produce errors. The tRNA identity elements, including the anticodon and acceptor stem, ensure specificity. Errors at this stage are the substrate for proofreading mechanisms.
Proofreading by ARS Editing Domains
In simple terms: If the wrong amino acid is attached, the synthetase can act as a quality inspector and remove it.
Many ARSs possess editing domains that hydrolyze mischarged aminoacyl-tRNAs, a process known as post-transfer editing. This editing can occur in cis within the same enzyme or in trans by separate editing factors. Structural and biochemical studies have revealed diverse editing mechanisms, including hydrolytic and cyclization pathways.
Trans-Editing Factors and Ribosome-Associated Quality Control
In simple terms: Other proteins can also correct mistakes, sometimes after the tRNA has left the synthetase.
In addition to ARS editing, trans-editing factors such as AlaXp and ProXp can hydrolyze mischarged tRNAs. Recent evidence indicates that human protein synthesis requires aminoacyl-tRNA pivoting during proofreading, suggesting dynamic interactions at the ribosome. Ribosome-associated quality control pathways can also detect and degrade aberrant products.
tRNA Pivoting and Conformational Dynamics
In simple terms: The tRNA can twist and change shape to help proofreading occur.
Structural studies have shown that tRNAs undergo conformational changes, or pivoting, during proofreading, which facilitates the recognition and hydrolysis of incorrect amino acids. This dynamic behavior is essential for efficient editing and may be regulated by cellular conditions.
Fidelity Checkpoints in Translation Initiation
In simple terms: Even before protein building starts, there are checks to ensure the right tRNA is used.
Initiation factor 3 (IF3) plays a role in the fidelity of initiator tRNA selection on the ribosome, adding another layer of quality control. This ensures that translation begins with the correct initiator tRNA, preventing errors from the outset.
Key Genes Involved in GO:0106074 aminoacyl-tRNA metabolism involved in translational fidelity
The following genes encode key components of the aminoacyl-tRNA proofreading and editing machinery, including ARSs with editing domains and trans-editing factors.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AARS1 | Alanyl-tRNA synthetase with editing domain | Mutations cause neurodevelopmental disorders; editing defects linked to neurodegeneration |
| AARS2 | Mitochondrial alanyl-tRNA synthetase | Mutations cause mitochondrial cardiomyopathy and myopathy |
| IARS1 | Isoleucyl-tRNA synthetase with editing domain | Editing defects associated with growth retardation and liver disease |
| LARS1 | Leucyl-tRNA synthetase with editing domain | Mutations cause infantile liver failure syndrome |
| VARS1 | Valyl-tRNA synthetase with editing domain | Mutations linked to neurodevelopmental disorders |
| MARS1 | Methionyl-tRNA synthetase with editing domain | Editing defects cause Charcot-Marie-Tooth disease |
| GARS1 | Glycyl-tRNA synthetase with editing domain | Mutations cause Charcot-Marie-Tooth disease type 2D |
| YARS1 | Tyrosyl-tRNA synthetase with editing domain | Mutations linked to Charcot-Marie-Tooth disease and cancer |
| KARS1 | Lysyl-tRNA synthetase with editing domain | Mutations cause hearing loss and neuropathy |
| FARSA | Phenylalanyl-tRNA synthetase alpha subunit | Editing defects associated with cancer |
| FARSB | Phenylalanyl-tRNA synthetase beta subunit | Mutations cause neurodevelopmental disorders |
| EPRS1 | Glutamyl-prolyl-tRNA synthetase | Editing domain; linked to cancer and immune regulation |
| DARS1 | Aspartyl-tRNA synthetase | Mutations cause hypomyelination with brainstem and spinal cord involvement |
| DARS2 | Mitochondrial aspartyl-tRNA synthetase | Mutations cause leukoencephalopathy |
| NARS1 | Asparaginyl-tRNA synthetase | Mutations linked to neurodevelopmental disorders |
| RARS1 | Arginyl-tRNA synthetase | Mutations cause hypomyelinating leukodystrophy |
| TARS1 | Threonyl-tRNA synthetase | Editing domain; mutations linked to neuropathy |
| HARS1 | Histidyl-tRNA synthetase | Mutations cause Charcot-Marie-Tooth disease and Usher syndrome |
How Is aminoacyl-tRNA metabolism involved in translational fidelity Regulated?
The proofreading and editing activities of aminoacyl-tRNA synthetases are regulated at multiple levels. Expression of ARSs can be modulated by the integrated stress response (ISR) and mTOR signaling, which coordinate translation with cellular stress. Post-translational modifications, such as phosphorylation, can affect editing efficiency. Additionally, alternative splicing generates ARS variants with altered editing capacities. The evolutionary history of ARSs reveals that editing domains have been gained and lost, suggesting adaptive regulation.
aminoacyl-tRNA metabolism involved in translational fidelity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GARS1 | Charcot-Marie-Tooth disease type 2D | Knock-in mouse model with editing-deficient GARS1 |
| AARS1 | Neurodevelopmental disorder with epilepsy | Patient-derived iPSCs with point mutations |
| MARS1 | Charcot-Marie-Tooth disease | CRISPR knockout of editing domain in cell lines |
| EPRS1 | Cancer progression | Overexpression in cancer cell lines |
| DARS2 | Leukoencephalopathy with brainstem and spinal cord involvement | Knockout zebrafish or mouse models |
Cancer
Dysregulation of aminoacyl-tRNA synthetases and their editing functions is increasingly linked to cancer. Overexpression of certain ARSs, such as EPRS1, promotes tumor growth, while editing defects can contribute to genomic instability and altered translation. The tRNA landscape in cancer reveals that mischarged tRNAs can affect signaling pathways and immune responses.
Neurodegeneration
Mutations in ARSs, particularly those affecting editing domains, cause Charcot-Marie-Tooth disease and other neuropathies. For example, mutations in GARS1, YARS1, and MARS1 lead to peripheral nerve degeneration, likely due to impaired proofreading and subsequent proteotoxic stress.
Mitochondrial Disorders
Mitochondrial ARSs (e.g., AARS2, DARS2) are essential for mitochondrial translation. Defects in their editing activities can cause severe mitochondrial diseases, including cardiomyopathy and leukoencephalopathy.
Ribosomopathies and Developmental Disorders
Impaired translational fidelity due to editing defects can manifest as ribosomopathies and neurodevelopmental disorders. Mutations in AARS1 and other ARSs are associated with developmental delay and microcephaly.
From aminoacyl-tRNA metabolism involved in translational fidelity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of editing domain affect translational fidelity? | Knockout of editing domain via CRISPR in HEK293T cells |
| How do disease-associated point mutations impact proofreading? | Point mutation knock-in using CRISPR in patient iPSCs |
| Can tagged editing factors be tracked in live cells? | Knock-in of fluorescent tags (e.g., GFP) at endogenous loci |
| What is the effect of ARS overexpression on cancer? | Overexpression of wild-type or mutant ARS in cancer cell lines |
| Which genes interact with editing factors? | CRISPR library screening with Ribo-seq readout |
| How does tRNA pivoting regulate proofreading? | Structural studies with mutant tRNAs and cryo-EM |
How to Study the aminoacyl-tRNA metabolism involved in translational fidelity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Ribo-seq | Ribosome occupancy and codon-specific translation errors | Quantifying misincorporation in editing mutants |
| RNA-seq | Transcriptome-wide changes in gene expression | Identifying stress responses to fidelity loss |
| tRNA sequencing | tRNA abundance and charging levels | Detecting mischarged tRNAs |
| Proteomics | Protein-level amino acid substitutions | Validating editing defects |
| Cryo-EM | Structural dynamics of editing complexes | Visualizing tRNA pivoting |
| CRISPR screening | Gene essentiality and interactions | Identifying modifiers of proofreading |
| In vitro aminoacylation assays | Enzymatic activity and editing efficiency | Characterizing ARS mutants |
| Fluorescence microscopy | Subcellular localization of editing factors | Tracking tRNA dynamics |
Ribosome Profiling (Ribo-seq)
Ribo-seq provides a snapshot of translating ribosomes at codon resolution, allowing detection of amino acid misincorporation events that arise from proofreading defects. By comparing wild-type and mutant cells, researchers can quantify changes in translational fidelity.
RNA Sequencing and tRNA Profiling
RNA-seq can reveal changes in tRNA expression and modifications, while specialized tRNA sequencing (e.g., ARM-seq) can detect mischarged tRNAs. These methods help link editing defects to global translation changes.
Mass Spectrometry-Based Proteomics
Proteomics can identify proteins with amino acid substitutions caused by mischarging, providing direct evidence of fidelity loss. This approach is powerful for validating editing defects in disease models.
Structural Biology and Imaging
Cryo-EM and X-ray crystallography reveal how editing domains recognize and hydrolyze mischarged tRNAs. Fluorescence microscopy can track tRNA dynamics in live cells.
How CRISPR Can Be Used to Study GO:0106074 aminoacyl-tRNA metabolism involved in translational fidelity
Knockout
CRISPR knockout of ARS editing domains or trans-editing factors allows researchers to assess the consequences of lost proofreading on translation and cell viability. For example, knockout of the editing domain of AARS1 in human cells leads to increased misincorporation and activation of stress pathways.
Point Mutation
Introducing disease-associated point mutations into ARS genes via CRISPR base editing or HDR enables precise modeling of editing defects. Such models can reveal how specific mutations alter proofreading activity and contribute to neuropathy or cancer.
Knock-in
Knock-in of tagged versions of editing factors (e.g., GFP or HA) at endogenous loci facilitates live-cell imaging and proteomic studies. This approach preserves native regulation and allows tracking of protein dynamics.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of wild-type or mutant ARSs can model gain-of-function effects observed in cancer. Overexpression of EPRS1, for instance, promotes tumorigenesis and alters translation.
How EDITGENE Supports aminoacyl-tRNA metabolism involved in translational fidelity Research
Researchers studying aminoacyl-tRNA metabolism involved in translational fidelity-related genes often need to determine whether a candidate gene is causally involved in proofreading, how mutations affect editing activity, and what downstream pathways are perturbed. EDITGENE provides a comprehensive suite of CRISPR services to address these questions with precision and scale.
Contact EDITGENE today to design your custom CRISPR model for aminoacyl-tRNA metabolism involved in translational fidelity research.
Frequently Asked Questions About aminoacyl-tRNA metabolism involved in translational fidelity
What is GO:0106074?
GO:0106074 is a Gene Ontology biological process term that describes the proofreading and editing of aminoacyl-tRNAs to ensure translational fidelity, including detection and removal of incorrect amino acids [2, 7].
What genes are involved in aminoacyl-tRNA metabolism involved in translational fidelity?
Key genes include aminoacyl-tRNA synthetases such as AARS1, GARS1, MARS1, and trans-editing factors like AlaXp [4, 7].
How does proofreading prevent amino acid misincorporation?
Editing domains in ARSs hydrolyze mischarged tRNAs, preventing incorrect amino acids from entering the ribosome and being incorporated into proteins.
What diseases are linked to defects in aminoacyl-tRNA proofreading?
Defects are linked to Charcot-Marie-Tooth disease, mitochondrial disorders, cancer, and neurodevelopmental disorders.
What methods are used to study translational fidelity?
Ribo-seq, tRNA sequencing, proteomics, and structural biology are commonly used to study fidelity mechanisms [3, 6].
How can CRISPR be used to study GO:0106074?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of ARS genes to assess their roles in proofreading.
What is the role of tRNA pivoting in proofreading?
tRNA pivoting refers to conformational changes that facilitate the recognition and hydrolysis of incorrect amino acids during proofreading.
Are there therapeutic targets in this pathway?
Yes, ARSs and their editing domains are potential targets for antibiotics and cancer therapeutics [6, 7].
How does the integrated stress response relate to translational fidelity?
The ISR is activated by translational errors and can modulate ARS expression to restore fidelity.
What cell models are available for studying aminoacyl-tRNA metabolism?
EDITGENE provides knockout, point mutation, knock-in, and overexpression cell models for ARS genes and related factors.
Conclusion
GO:0106074, aminoacyl-tRNA metabolism involved in translational fidelity, is a fundamental quality-control process that safeguards protein synthesis. Its mechanisms, from ARS editing to tRNA pivoting, are conserved yet diverse, and their failure contributes to a range of human diseases [6, 7]. Advances in CRISPR technology and sequencing methods are accelerating our understanding of this pathway, offering new avenues for therapeutic intervention. Continued research into the genes and regulatory networks of GO:0106074 will illuminate basic biology and provide targets for treating cancer, neurodegeneration, and mitochondrial disorders.
References
- 2. Kuncha SK et al.. 2019. Chiral checkpoints during protein biosynthesis.. J Biol Chem 294(45):16535-16548 PMID: 31591268
- 3. Sapkota D et al.. 2025. Human protein synthesis requires aminoacyl-tRNA pivoting during proofreading.. Nat Commun 16(1):8202 PMID: 40897704
- 4. Giegé R et al.. 2023. The tRNA identity landscape for aminoacylation and beyond.. Nucleic Acids Res 51(4):1528-1570 PMID: 36744444
- 5. Singh J et al.. 2025. Role of the initiation factor 3 in the fidelity of initiator tRNA selection on ribosome.. IUBMB Life 77(1):e2927 PMID: 39578968
- 6. Jian N et al.. 2026. The tRNA landscape in cancer: from pathogenesis to therapeutic interventions.. Acta Biochim Biophys Sin (Shanghai) 58(6):1187-1212 PMID: 42305048
- 7. Francklyn CS. 2008. DNA polymerases and aminoacyl-tRNA synthetases: shared mechanisms for ensuring the fidelity of gene expression.. Biochemistry 47(45):11695-703 PMID: 18850722
- 8. Chaliotis A et al.. 2017. The complex evolutionary history of aminoacyl-tRNA synthetases.. Nucleic Acids Res 45(3):1059-1068 PMID: 28180287
